Simulated-1g1c: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
Line 586: Line 586:
== Notes ==
== Notes ==


=== Towards better completeness: using the first two frames ===
=== Towards better completeness: using the first two frames instead of only the first ===


We might want better (anomalous) completeness than what is given by only the very first frame of each dataset. To this end, we change in the XDS.INP part of our script :
We might want better (anomalous) completeness than what is given by only the very first frame of each dataset. To this end, we change in the XDS.INP part of our script :
Line 645: Line 645:
  Final R-work = 0.2244, R-free = 0.2504
  Final R-work = 0.2244, R-free = 0.2504


so: better R-free is obtained from better data.
so: '''better R-free is obtained from better data.'''


The statistics from SHELXD and SHELXE don't look better - they were already quite good with a single frame per dataset. The statistics printed by SHELXE (for the correct hand) are:
The statistics from SHELXD and SHELXE don't look better - they were already quite good with a single frame per dataset. The statistics printed by SHELXE (for the correct hand) are:
Line 669: Line 669:
   6  0.5158  0.4788  0.0406  4.7  5/1.45  3/4.94 4/7.85 1/21.38 5/23.30
   6  0.5158  0.4788  0.0406  4.7  5/1.45  3/4.94 4/7.85 1/21.38 5/23.30


Using these four sites (and standard parameters otherwise, I obtained from the [http://cci.lbl.gov/cctbx/phase_o_phrenia.html cctbx - Phase-O-Phrenia server] the following
=== Why this is difficult to solve with SAD phasing ===
 
In the original publication ("Structural evidence for a possible role of reversible disulphide bridge formation in the elasticity of the muscle protein titin" Mayans, O., Wuerges, J., Canela, S., Gautel, M., Wilmanns, M. (2001) Structure 9: 331-340 ) we read:
 
"This crystal form contains two molecules in the asymmetric unit. They are related by a noncrystallographic two-fold axis, parallel to the crystallographic b axis, located at X = 0.25 and Z = 0.23. This arrangement results in a peak in the native Patterson map at U = 0.5, V = 0, W = 0.47 of peak height 26 σ (42% of the origin peak)."
 
Unfortunately, the arrangement of substructure sites has translational symmetry, and may be related to a centrosymmetric arrangement. Indeed, the original structure was solved using molecular replacement.
 
Using the four sites as given by SHELXE (and default parameters otherwise), I obtained from the [http://cci.lbl.gov/cctbx/phase_o_phrenia.html cctbx - Phase-O-Phrenia server] the following
  Plot of relative peak heights:
  Plot of relative peak heights:
   
   
Line 712: Line 720:


so the strongest peak corresponds to the translation of molecules (0,0.5,0) but the origin peak is at 1/2 of that size, which appears significant. (I cannot interpret the plot of relative peak heights, though <big>☹</big>)
so the strongest peak corresponds to the translation of molecules (0,0.5,0) but the origin peak is at 1/2 of that size, which appears significant. (I cannot interpret the plot of relative peak heights, though <big>☹</big>)
=== Why this is difficult to solve with SAD phasing ===
In the original publication ("Structural evidence for a possible role of reversible disulphide bridge formation in the elasticity of the muscle protein titin" Mayans, O., Wuerges, J., Canela, S., Gautel, M., Wilmanns, M. (2001) Structure 9: 331-340 ) we read:
"This crystal form contains two molecules in the asymmetric unit. They are related by a noncrystallographic two-fold axis, parallel to the crystallographic b axis, located at X = 0.25 and Z = 0.23. This arrangement results in a peak in the native Patterson map at U = 0.5, V = 0, W = 0.47 of peak height 26 σ (42% of the origin peak)."
Unfortunately this translates into a almost centrosymmetric arrangement of substructure sites (check with [http://cci.lbl.gov/cctbx/phase_o_phrenia.html]). Indeed, the original structure was solved using molecular replacement.
2,684

edits

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Navigation menu